Search research articles
Contact Us
Filters
Showing results (51-60 of 179) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Cancer
|
October 15, 2018
Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis
Gabrielle B Rocque, Courtney P Williams, Kelly M Kenzik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2016
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
George A Dominguez, Thomas Condamine, Sridevi Mony, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer
Gabrielle B Rocque, Courtney P Williams, Bradford E Jackson, et al.
Blood
|
April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Leukemia & Lymphoma
|
February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Plos One
|
September 9, 2017
Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans
Madison R Chandler, Kimberly S Keene, Johanna M Tuomela, et al.
Cancer Immunology, Immunotherapy : CII
|
October 19, 2018
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
Tyler R McCaw, Mei Li, Dmytro Starenki, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2018
O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity
Shamik Das, Sarah K Bailey, Brandon J Metge, et al.
Page
of 18
Search research articles
Search
Showing results (51-60 of 179) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Cancer
|
October 15, 2018
Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis
Gabrielle B Rocque, Courtney P Williams, Kelly M Kenzik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2016
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
George A Dominguez, Thomas Condamine, Sridevi Mony, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer
Gabrielle B Rocque, Courtney P Williams, Bradford E Jackson, et al.
Blood
|
April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Leukemia & Lymphoma
|
February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Plos One
|
September 9, 2017
Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans
Madison R Chandler, Kimberly S Keene, Johanna M Tuomela, et al.
Cancer Immunology, Immunotherapy : CII
|
October 19, 2018
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
Tyler R McCaw, Mei Li, Dmytro Starenki, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2018
O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity
Shamik Das, Sarah K Bailey, Brandon J Metge, et al.
Page
of 18